Atossa Therapeutics, Inc.
ATOSHealthcare|Biotechnology|US
$2.12
+0.10 (+4.95%)
DCF Value
$4.35
Tangible Book / Share
$3.01
Cash / Share
$2.93
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05607004 (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | Breast Neoplasms, Invasive Breast Cancer | P2 | Active | 87 | Open-label | (Z)-endoxifen, goserelin |
| NCT02539615 A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old | Breast Cancer, Preneoplastic Conditions, BRCA | P3 | Withdrawn | — | Open-label | — |
| NCT07869732 (Z)-Endoxifen in Girls With MAS-Associated Peripheral Precocious Puberty | Precocious Puberty, Gonadotropin-dependent | P2 | Not Yet Recruiting | 6 | Open-label | (Z)-endoxifen |
| NCT05068388 Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density | Breast Density | P2 | Completed | 240 | RCT, Double-blind | Z-Endoxifen, Placebo |
| NCT04616430 Topical Endoxifen in Women | Mammographic Breast Density | P2 | Completed | 90 | RCT, Double-blind | Topical endoxifen, Placebo |
| NCT02540330 A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant | Female Breast Carcinoma, Female Ductal Carcinoma In Situ | P2 | Terminated | 3 | Open-label | Fulvestrant |
| NCT04519788 AT-301 Nasal Spray in Healthy Adults | Healthy | P1 | Completed | 32 | RCT, Double-blind | AT-301B, AT-301A |
| NCT02218385 ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid | Breast Neoplasms | Completed | 52 | — | — | |
| NCT02121873 The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage | Breast Cancer, Preneoplastic Conditions | Completed | 6 | — | — |